The mechanism of action of T-VEC exists of three phases (1): inducing a lytic cancer cell death with release of tumor-associated antigens and immune stimulatory molecules (“danger” signals) (2), attracting and activating immature DC through production of GM-CSF and (3) inducing an adaptive immune response against the cancer cells (19). The gene discussed is CSF2; the disease is cancer.